KR20070086663A - 암 백신 보조제로서 알파 티모신 펩티드류 - Google Patents

암 백신 보조제로서 알파 티모신 펩티드류 Download PDF

Info

Publication number
KR20070086663A
KR20070086663A KR1020077014527A KR20077014527A KR20070086663A KR 20070086663 A KR20070086663 A KR 20070086663A KR 1020077014527 A KR1020077014527 A KR 1020077014527A KR 20077014527 A KR20077014527 A KR 20077014527A KR 20070086663 A KR20070086663 A KR 20070086663A
Authority
KR
South Korea
Prior art keywords
cancer
vaccine
cells
subject
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077014527A
Other languages
English (en)
Korean (ko)
Inventor
거스타보 안토니오 모비글리아
알프레드 알. 루돌프
Original Assignee
사이클론 파아머슈티컬 인코오퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사이클론 파아머슈티컬 인코오퍼레이티드 filed Critical 사이클론 파아머슈티컬 인코오퍼레이티드
Publication of KR20070086663A publication Critical patent/KR20070086663A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020077014527A 2004-12-06 2005-12-06 암 백신 보조제로서 알파 티모신 펩티드류 Ceased KR20070086663A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63317504P 2004-12-06 2004-12-06
US60/633,175 2004-12-06

Publications (1)

Publication Number Publication Date
KR20070086663A true KR20070086663A (ko) 2007-08-27

Family

ID=36578462

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077014527A Ceased KR20070086663A (ko) 2004-12-06 2005-12-06 암 백신 보조제로서 알파 티모신 펩티드류

Country Status (15)

Country Link
US (1) US20100092499A1 (https=)
EP (1) EP1835931A4 (https=)
JP (1) JP2008523067A (https=)
KR (1) KR20070086663A (https=)
CN (1) CN101072582B (https=)
AU (1) AU2005314271B2 (https=)
BR (1) BRPI0518571A2 (https=)
CA (1) CA2588685A1 (https=)
EA (1) EA015510B1 (https=)
IL (1) IL183264A (https=)
MX (1) MX2007006717A (https=)
NO (1) NO20072705L (https=)
NZ (1) NZ555571A (https=)
UA (1) UA90493C2 (https=)
WO (1) WO2006062917A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170070091A (ko) * 2014-10-21 2017-06-21 사이클론 파아머슈티컬 인코오퍼레이티드 면역 자극인자를 이용한 암의 치료

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317583A1 (en) * 2007-12-14 2010-12-16 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
EP2427213B1 (en) 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
WO2012109106A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
JP6385280B2 (ja) * 2012-01-20 2018-09-05 トーメ クロイツ、フェルナンド 自家癌細胞ワクチン
JP2015510887A (ja) * 2012-03-08 2015-04-13 サイクローン・ファーマシューティカルズ・インコーポレイテッドＳｃｉＣｌｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 化膿性鼻副鼻腔炎の処置のためのチモシンαの使用
CN107281476B (zh) * 2017-04-06 2020-11-24 中国医科大学 一种抗原肽RL-佐剂CpGODN7909偶联物及其制备方法和应用
RU2645957C1 (ru) * 2017-04-10 2018-02-28 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения лучевых повреждений мочевого пузыря
RU2663468C1 (ru) * 2017-09-25 2018-08-06 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US653758A (en) * 1900-03-20 1900-07-17 Austin Gale Hay-stacking device.
DE2604845A1 (de) 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
JPH0420624A (ja) * 1990-02-06 1992-01-24 Kanji Yokoe 勾配側溝施工法及び当該工法に使用する可変側溝
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
MXPA02000192A (es) * 1999-06-30 2004-08-12 Corixa Corp Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
ES2299626T3 (es) * 2001-10-26 2008-06-01 Rhode Island Hospital Aumento de timosina para asegurar una inmunizacion genetica.
AU2002342151B2 (en) * 2001-10-26 2007-07-19 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
JP2005537246A (ja) 2002-06-28 2005-12-08 サイクローン・ファーマシューティカルズ・インコーポレイテッド サイマルファシンを用いて腫瘍抗原発現をアップレギュレートする方法
EA008037B1 (ru) * 2003-03-28 2007-02-27 Сциклон Фармасьютикалс, Инк. ЛЕЧЕНИЕ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ГРИБАМИ p. ASPERGILLUS, С ПОМОЩЬЮ ТИМОЗИНА АЛЬФА 1
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
EP2427213B1 (en) * 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170070091A (ko) * 2014-10-21 2017-06-21 사이클론 파아머슈티컬 인코오퍼레이티드 면역 자극인자를 이용한 암의 치료

Also Published As

Publication number Publication date
CA2588685A1 (en) 2006-06-15
EP1835931A4 (en) 2008-12-17
AU2005314271B2 (en) 2011-06-16
MX2007006717A (es) 2007-08-06
NZ555571A (en) 2009-02-28
EA200701166A1 (ru) 2008-02-28
JP2008523067A (ja) 2008-07-03
EP1835931A2 (en) 2007-09-26
AU2005314271A1 (en) 2006-06-15
BRPI0518571A2 (pt) 2008-11-25
CN101072582A (zh) 2007-11-14
IL183264A (en) 2010-12-30
IL183264A0 (en) 2007-09-20
WO2006062917A2 (en) 2006-06-15
US20100092499A1 (en) 2010-04-15
NO20072705L (no) 2007-09-05
UA90493C2 (ru) 2010-05-11
CN101072582B (zh) 2012-06-27
EA015510B1 (ru) 2011-08-30
WO2006062917A3 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
Kurosawa et al. Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes
KR20210120066A (ko) 췌장암 치료용 약학 조성물
US9694059B2 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
CN113474004A (zh) 用于治疗肿瘤的包含抗cd19抗体和自然杀伤细胞的药物组合
AU2003265948A1 (en) Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
Kjaergaard et al. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine
US20210353674A1 (en) Pharmaceutical composition for use in the treatment of pancreatic cancer
KR20070086663A (ko) 암 백신 보조제로서 알파 티모신 펩티드류
ZA200703528B (en) Immunotherapeutic formulations with Interleukin-2-neutralising capacity
US20230355678A1 (en) Methods for improving t cell efficacy
Bella-Carreño Evaluation of modified vaccinia virus Ankara based locoregional immunotherapy in peritoneal carcinomatosis models
Zhang Cancer Immunotherapy
KR20230085116A (ko) 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
Li et al. Anti-tumour and immune enhancing activities of MLAA-22 379–387 on acute myeloid leukemia
Fend et al. Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-a Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
Whiteside The Role of Immune Effector Cells in Immunotherapy of Head and Neck Cancer
Mansoor et al. Genetically Modified T Cell Therapy Optimisation of the Chimeric T Cell Receptor for Cancer Therapy
HK1113374B (en) Immunotherapeutic formulations with interleukin-2-neutralising capacity

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070626

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20101203

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120823

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130226

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120823

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I